10:29 AM EDT, 07/09/2024 (MT Newswires) -- Harrow (HROW) said Tuesday it agreed to make its products including Iheezo 3%, Vigamox and Ilevro available to Apexus through the 340B prime vendor program.

Apexus manages the 340B Prime Vendor Program, a contract awarded by Health Resources and Services Administration, an agency of the US Department of Health and Human Services, to ensure access to discounted medications.

Shares of the eyecare pharmaceutical company were up about 1.5% in recent trading.

Price: 22.80, Change: +0.34, Percent Change: +1.51